ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Current status and challenges of immunotherapy in ALK rearranged NSCLC.Frontiers in oncology · 2022Pooled it
- Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma.Future oncology (London, England) · 2025Trial
- High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.Journal for immunotherapy of cancer · 2024Trial
- Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.Journal for immunotherapy of cancer · 2021Trial
- Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.Journal for immunotherapy of cancer · 2020Trial
- Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.Journal for immunotherapy of cancer · 2020Trial
- Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.Journal for immunotherapy of cancer · 2020Trial
- Genetic Engineering of Tumor-Infiltrating Lymphocytes (TIL) via a T-Editor Platform to Enhance Anti-Tumor Activity.Cancer science · 2026Article
- Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.Med (New York, N.Y.) · 2026Article
- Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.Cancer · 2026Review
- Phenotypic Analysis of 26 Cultured TILs Derived From Japanese Melanoma Tissues.The Journal of dermatology · 2026Article
- PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.Journal of translational medicine · 2026Article
- Does tumor-infiltrating lymphocyte therapy improve survival outcomes in patients with advanced melanoma?Frontiers in medicine · 2026Review
- Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation.Therapeutic advances in medical oncology · 2026Article
- Mucosal Melanoma: An Overview of Recent Therapies.Current pharmaceutical design · 2026Review
- CRISPR-screen informed engineered T cell therapies.Frontiers in immunology · 2026Review
- Mucosal Melanoma: Treatment Strategies for a Heterogeneous Disease.Current pharmaceutical design · 2026Article
- Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma.Genome medicine · 2025Article
- Facts and Hopes for Neoantigen-Enriched TIL.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 5 institutions in 2 countries.
Marie-Andrée Forget *Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Cara Haymaker *Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Kenneth R HessDepartment of Biostatistics, The University of Texas MDACC, Houston, Texas.
Yuzhong Jeff MengBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Caitlin CreasyDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.ORCID 0000-0002-6271-0337
Tatiana KarpinetsDepartment of Genomic Medicine, The University of Texas MDACC, Houston, Texas.
Orenthial J FulbrightDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Jason RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Scott E WoodmanDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Young Uk KimDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Donastas Sakellariou-ThompsonDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Ankit BhattaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Arely WahlDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Esteban FloresDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Shawne T ThorsenDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
René J TaveraDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Renjith RamachandranDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Audrey M GonzalezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Christopher L TothDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Seth WardellDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Rahmatu MansarayDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Vruti PatelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Destiny Joy CarpioDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Carol VaughnDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Chantell M FarinasDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Portia G VelasquezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Wen-Jen HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Sapna P PatelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Adi DiabDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Isabella C GlitzaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Hussein TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Michael K WongDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Suzanne CainDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Merrick I RossDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Jeffrey E GershenwaldDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Anthony LucciDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Richard RoyalDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Janice N CormierDepartment of Surgical Oncology, The University of Texas MDACC, Houston, Texas.
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MDACC, Houston, Texas.
Laszlo G RadvanyiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Carlos A Torres-CabalaDepartment of Pathology, The University of Texas MDACC, Houston, Texas.
Rameen BeroukhimBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.
Rodabe N AmariaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. cbernatchez@mdanderson.org rnamaria@mdanderson.org.
Chantale BernatchezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. cbernatchez@mdanderson.org rnamaria@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USAnesthesiology and Surgical Oncology Research Group · USBroad Institute · USUniversity of Houston · USCenter for Genomic Science · IT
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MGenetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9MDC Vaccination to Enhance Adoptive T Cell TransferR01CA111999 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK · 2006 to 2010
$1.8MBiomarkers and Resistance Mechanisms in Melanoma T-cell TherapyR01CA184845 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK, MULE, JAMES J. · 2014 to 2018
$1.7MFunctional Attributes of a CD8+BTLA+ T cell subset in Adoptive T Cell TherapyR21CA178580 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERNATCHEZ, CHANTALE · 2013 to 2014
$377kNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA111999NCI NIH HHS R01 CA184845NCI NIH HHS R01 CA188228NCI NIH HHS R21 CA178580
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedCombined Modality TherapyCTLA-4 AntigenFemaleHumansImmunotherapy, AdoptiveInterleukin-9Lymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedNeoplasm MetastasisNeoplasms, Second PrimaryProgrammed Cell Death 1 ReceptorProgression-Free SurvivalCTLA-4 AntigenCTLA4 protein, humanIL9 protein, humanInterleukin-9PDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.